The ARTESIA trial demonstrates that Apixaban effectively reduces the risk of stroke or systemic embolism in patients with subclinical atrial fibrillation. Despite the increased risk of major bleeding, the severity of prevented stroke events outweighs the severity of bleeding events caused by the drug. This could potentially change the approach to managing subclinical atrial fibrillation in patients at high risk of stroke. Original article here.

ABOUT THE STATE OF HEALTH

The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

FOLLOW US

Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Threads: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠threads.net/@medzcool

Episode ID: 1000642802472

GUID: 136b86ea-1fad-42c1-861a-aa86045f7d57

Release Date: 24/01/2024, 21:27:33